Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic lethality between <i>CCNE1</i> amplification and loss of <i>BRCA1</i>

11 Nov 2013

Abstract excerpt

High-grade serous ovarian cancers (HGSCs) are characterized by a high frequency of TP53 mutations, BRCA1/2 inactivation, homologous recombination dysfunction, and widespread copy number changes. Cyclin E1 (CCNE1) gene amplification has been reported to occur independently of BRCA1/2 mutation, and it is associated with primary treatment failure and reduced patient survival. Insensitivity of CCNE1-amplified tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24218601
DOI: 10.1073/pnas.1314302110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic lethality between <i>CCNE1</i> amplification and loss of <i>BRCA1</i>PMID 24218601Read ↗

CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombinationSemantic proximity Read ↗

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamicsSemantic proximity Read ↗

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cellsSemantic proximity Read ↗

Proteogenomic discovery of <i>RB1</i> -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targetsSemantic proximity Read ↗

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cellsSemantic proximity Read ↗

Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2Semantic proximity Read ↗

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsSemantic proximity Read ↗

Cyclin E1 protein is stabilized in <i>BRCA1</i> mutated breast cancers leading to synergy between CDK2 and PARP inhibitorsSemantic proximity Read ↗

Uev1A counteracts oncogenic <i>Ras</i> stimuli in both polyploid and diploid cellsSemantic proximity Read ↗

Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian CancerSemantic proximity Read ↗

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT InhibitionSemantic proximity Read ↗

Gene amplification <i>CCNE1</i> is related to poor survival and potential therapeutic target in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.